Citicoline (CDP-choline) is not established as protection against glaucoma. Small trials looked at electrical measures of the optic nerve.
Small trials of oral or topical citicoline, including work from the Parisi and Rossetti groups, demonstrate changes in electrophysiological measures. Whether citicoline slows vision loss is not established. It is not accurate to say it protects against glaucoma.
This topic has almost no search volume. It stays because clinicians look for the adjunct evidence, and because a quiet page should still tell the truth. Bring the question to an ophthalmologist who can see the field of vision, not to a supplement label.
Study names are working references and still need PMID confirmation. This page does not invent them.
| Question | Best evidence | Tier | Bottom line |
|---|---|---|---|
| Glaucoma as an adjunct | Small RCTs of oral or topical citicoline | T1 (small) | Changes in electrophysiological measures; effect on vision loss not established |
Side effects · Doses used in studies · What to ask your doctor
Most glaucoma care centers on one number: pressure inside the eye. Lowering that pressure, usually with medicated drops or surgery, is the main proven way to slow the disease. Yet some people keep losing vision even when their pressure is well controlled. That gap is why researchers have asked whether the optic nerve itself can be supported directly, and it is the opening that citicoline (CDP-choline) research stepped into.
Citicoline is a compound that supplies building blocks used in making cell membranes, and laboratory work suggests it may support membrane phospholipid synthesis. That mechanism is part of why it drew interest as a possible nerve-protective agent. But the step from a plausible mechanism to a proven benefit for people is large. Preclinical neuroprotection findings stay in the lab until trials in patients confirm them. For glaucoma, that confirmation has not happened.
The glaucoma work on citicoline comes from small trials, including studies from the Parisi and Rossetti groups. Some used oral citicoline and some used topical drops. What they measured matters as much as what they found.
The main outcome in this research was electrophysiological: tests that record electrical signals along the visual pathway, from the retina to the brain. These tests can detect changes in how the optic nerve functions, sometimes before changes show up in a person's vision. The trials reported changes in these electrical measures in people taking citicoline.
That finding is real, but it is also limited. An electrical measure is a surrogate. It stands in for the thing patients and doctors actually care about: whether a person keeps their visual field over years. A measure can move in a favorable direction while the disease itself continues to progress. Small trials running over short periods cannot answer the long question. Whether citicoline slows actual vision loss in glaucoma is not established.
It would be easy to read "changes in electrophysiological measures" as "citicoline protects the optic nerve." That reading goes beyond the evidence. Here is what the current record does and does not support.
The record supports this: in small trials, oral or topical citicoline was associated with changes in electrical measures of the visual pathway. The record does not support any of these statements:
None of those claims have been tested in the way that would be needed to make them: large trials, long follow-up, and vision-based endpoints. Until that kind of trial exists, the honest summary is the one at the top of this page. A measure changed. Vision loss is not settled.
This pattern is not unique to glaucoma. In stroke, early meta-analyses suggested citicoline might help recovery, but the largest trial, the ICTUS trial of about 2,300 people, found no improvement in 90-day recovery versus placebo. In traumatic brain injury, the COBRIT trial found no benefit on functional or cognitive outcomes. The lesson across conditions is consistent: early or surrogate findings need big, hard-endpoint trials before they mean something for patients. Glaucoma has not had that trial.
Readers sometimes notice that the small trials used both oral citicoline and topical formulations and wonder which one is "the" studied approach. There is no answer to give. The trials were small, the methods varied, and this page does not turn either route into a regimen.
It is also worth being clear about what citicoline is in the United States. It is sold as a dietary supplement, not as an FDA-approved drug. No citicoline product, oral or otherwise, is approved to treat glaucoma or any other disease. The topical formulations in the research literature are not products you can assume are equivalent to anything on a store shelf.
If you have glaucoma or are being monitored for it, the proven part of your care has not changed. Pressure-lowering treatment, regular visual field testing, and follow-up with an ophthalmologist remain the foundation. Do not stop, skip, or reduce prescribed eye drops because of anything on this page. Vision lost to glaucoma does not come back, and the treatments that protect it are already in your doctor's hands, not in a supplement aisle.
If you are thinking about adding citicoline on top of your prescribed care, that is a conversation for your ophthalmologist. Citicoline is generally well tolerated at the doses used in trials, which ranged from 250 to 2,000 mg per day, with mild side effects such as stomach upset, headache, and insomnia reported. Data in pregnancy and breastfeeding are lacking. But "well tolerated" is not the same as "shown to help your eyes," and your ophthalmologist is the person who can weigh the small research base against your specific situation. The page on questions to ask your doctor can help you prepare for that visit.
For context on tolerability, see citicoline side effects. For the doses that appeared in studies, see citicoline doses used in studies. Neither page is personal medical advice.
If a new study appears, a few questions will tell you how much weight to give it.
First, how many people were in it? Small trials can only detect large effects and are prone to results that fade on repetition. Second, what was the endpoint? A change in an electrical or imaging measure is not the same as a change in vision. Third, how long did it run? Glaucoma progresses over years, so a trial lasting months cannot show whether the disease was slowed. Fourth, what was it compared against? A comparison with no treatment or placebo answers a different question than a comparison added to standard pressure-lowering care.
Until a large trial with vision-based outcomes and long follow-up reports results, the status of citicoline in glaucoma stays where it is: an interesting signal in surrogate measures, with the outcome that matters still unproven.
Citicoline is not established as protection against glaucoma. Small trials from groups including Parisi and Rossetti showed changes in electrophysiological measures of the optic nerve with oral or topical use. Whether that translates into slower vision loss has not been shown, and it is not accurate to say citicoline protects against glaucoma. Prescribed pressure-lowering treatment and regular monitoring remain the proven approach, and no change to them should be based on this page. For a broader look at how citicoline has performed across conditions, including the large negative trials in stroke and brain injury, see the evidence overview.
That claim is not supported. Small trials show changes in electrical measures. An effect on vision loss is not established.
No. Do not change prescribed eye treatment based on this page.
The small trials include both oral and topical citicoline. This page does not turn that into a regimen.
No. It is here for accuracy, not for search volume.
An ophthalmologist who can relate a study measure to your visual fields.
Doses that appeared in studies are listed on the dosage page, not as personal advice.
This site reports what studies found. It does not choose a dose for you.